Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.57 |
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 12/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052904 | 0.92 | CTSC (0.67) | CTSCACEMEN1KMT2AERAP2 | |
| SCHEMBL30051220 | 0.90 | CTSC (0.62) | CTSCACEMEN1KMT2AERAP2 | |
| SCHEMBL30051511 | 0.90 | CTSC (0.64) | CTSCACEMEN1KMT2AERAP2 | |
| SCHEMBL30052005 | 0.90 | CTSC (0.69) | CTSCACEMEN1KMT2AERAP2 | |
| SCHEMBL30052793 | 0.89 | ECE1 (0.64) | CTSCACEMEN1KMT2AERAP2 | |
| SCHEMBL30051088 | 0.88 | CTSC (0.62) | CTSCACEMEN1KMT2AERAP2 | |
| SCHEMBL30052714 | 0.88 | ACE (0.64) | CTSCACEMEN1KMT2AERAP2 | |
| SCHEMBL30051716 | 0.88 | CTSC (0.61) | CTSCACEMEN1KMT2AERAP2 | |
| SCHEMBL30051770 | 0.87 | CTSC (0.65) | CTSCACEMEN1KMT2AERAP2 | |
| SCHEMBL30051830 | 0.87 | CTSC (0.71) | CTSCACEMEN1KMT2AERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | NGLY1, MAX, PTMA | CTSC 138/4885ACE 578/4885MEN1 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.